This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Yeung, S. J. Articles by Gagel, R. F. Search for Related Content PubMed PubMed Citation Articles by Yeung, S. J. Articles by Gagel, R. F. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB CALCIUM COMPOUNDS CALCIUM, ELEMENTAL Medline Plus Health Information Nutrition Palliative Care

Use of Long-Term Intravenous Phosphate Infusion in the Palliative Treatment of Tumor-Induced Osteomalacia

Sections of Endocrine Neoplasia and Hormonal Disorders (S.J.Y., P.S., R.F.G.) and Neurosurgery (I.E.M.), University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030

Address all correspondence and requests for reprints to: Robert F. Gagel, M.D., Section of Endocrine Neoplasia and Hormonal Disorders, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Box 15, Houston, Texas 77030.

Tumor-induced osteomalacia is characterized by paraneoplastic defects in vitamin D metabolism, proximal renal tubular functions, and phosphate transport. The resulting hypophosphatemia can cause generalized pain and muscle weakness, which significantly affect the quality of life of the patients. Palliative treatment with calcium, vitamin D, and phosphate replacement is indicated for patients in whom the causative tumor cannot be completely resected. In this report we describe a case of tumor-induced osteomalacia in whom adequate oral doses of phosphate could not be used because of gastrointestinal side-effects. Long term (3–6 months) iv phosphate infusion delivered by ambulatory infusion pumps in combination with oral calcium and vitamin D was used successfully to decrease pain and increase muscle strength. Careful monitoring of serum calcium, phosphate, and creatinine levels and reliable microinfusion technology have allowed the long term use of iv phosphate infusion without serious morbidity. This patient received repeated (three times) phosphate infusions over 8 yr, resulting in laboratory and symptomatic improvement after each course. However, this patient did suffer two episodes of central venous catheter-related infection. Because of potentially serious complications, such as severe hypocalcemia, calcified right ventricular thrombi, and nephrocalcinosis, long term iv phosphate infusion should be reserved for patients who cannot tolerate adequate doses of oral phosphate and for whom the benefits outweigh the risks.

This article has been cited by other articles:

				G. van Boekel, J. Ruinemans-Koerts, F. Joosten, P. Dijkhuizen, A. van Sorge, and H. de Boer Tumor producing fibroblast growth factor 23 localized by two-staged venous sampling Eur. J. Endocrinol., March 1, 2008; 158(3): 431 - 437. [Abstract] [Full Text] [PDF]

				T. O. Carpenter Oncogenic Osteomalacia -- A Complex Dance of Factors N. Engl. J. Med., April 24, 2003; 348(17): 1705 - 1708. [Full Text] [PDF]

				K. Sato, T. Obara, K. Yamazaki, M. Kanbe, K. Nakajima, A. Yamada, T. Yanagisawa, Y. Kato, T. Nishikawa, and K. Takano Somatic Mutations of the MEN1 Gene and Microsatellite Instability in a Case of Tertiary Hyperparathyroidism Occurring during High Phosphate Therapy for Acquired, Hypophosphatemic Osteomalacia J. Clin. Endocrinol. Metab., November 1, 2001; 86(11): 5564 - 5571. [Abstract] [Full Text] [PDF]